Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus casei + omega-3
- Development stage
- Unknown
- Lead developer
- US Pharmaceutical Corporation
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus casei + omega-3 is a combination dietary supplement containing the probiotic strain Lactobacillus casei (KE-99) and omega-3 fatty acids derived from fish oil. The product is designed to support digestive and immune system health by combining the benefits of probiotics—which help maintain gut flora balance and may improve gastrointestinal comfort—with those of omega-3 fatty acids, which are essential fats involved in cellular function and anti-inflammatory processes. The formulation claims that the addition of omega-3 enhances the growth, recovery, and efficacy of the probiotic by up to 30%. It is marketed for adults and children over 12 years old as an over-the-counter supplement taken once daily[1][2][3].
- Brand names
- Restora
- Other names
- lactobacillus casei ke-99 enhanced with omega-3probiotic KE-99 + fish oilprobiotic plus fish oil capsule
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)COXPPARG (Peroxisome proliferator-activated receptor gamma)Gastrointestinal microbiota
Beyond the preview
Go deeper on lactobacillus casei + omega-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus casei + omega-3.